CancerNetwork articleshttps://www.cancernetwork.com/newsCancerNetwork articles© 2026 MJH Life Sciences™ and CancerNetwork. All rights reserved.Fri, 19 Jun 2026 21:22:50 +00005en-us14447https://www.cancernetwork.com/newshttps://www.cancernetwork.com/logo.webphttps://www.cancernetwork.com/view/trident-trial-finds-no-survival-benefit-with-earlier-tumor-treating-fields-usehttps://www.cancernetwork.com/view/trident-trial-finds-no-survival-benefit-with-earlier-tumor-treating-fields-use<![CDATA[TRIDENT failed to show an OS benefit for TTFields started during chemoradiation vs the maintenance-phase approach in newly diagnosed glioblastoma.]]>Fri, 19 Jun 2026 20:00:00 GMTCancerNetworkusCancerNetwork Articleshttps://www.cancernetwork.com/view/fda-accepts-sc-mosunetuzumab-combo-sbla-in-relapsed-refractory-lbclhttps://www.cancernetwork.com/view/fda-accepts-sc-mosunetuzumab-combo-sbla-in-relapsed-refractory-lbcl<![CDATA[Findings from the phase 3 SUNMO trial support the regulatory decision regarding the mosunetuzumab-based regimen for this relapsed/refractory population.]]>Fri, 19 Jun 2026 17:00:00 GMTCancerNetworkusCancerNetwork Articleshttps://www.cancernetwork.com/view/asco-2026-key-insights-in-renal-cell-carcinoma-merkel-cell-carcinoma-and-chronic-myeloid-leukemiahttps://www.cancernetwork.com/view/asco-2026-key-insights-in-renal-cell-carcinoma-merkel-cell-carcinoma-and-chronic-myeloid-leukemia<![CDATA[In an expert-led review of pivotal clinical trial data presented at the 2026 ASCO Annual Meeting, CancerNetwork® spoke with oncology experts in the renal cell carcinoma (RCC), Merkel cell carcinoma, and chronic myeloid leukemia (CML) spaces to break down key abstracts at the conference.]]>Fri, 19 Jun 2026 16:00:00 GMTCancerNetworkusCancerNetwork Articleshttps://www.cancernetwork.com/view/3-things-you-should-know-about-cutaneous-squamous-cell-carcinomahttps://www.cancernetwork.com/view/3-things-you-should-know-about-cutaneous-squamous-cell-carcinoma<![CDATA[A panel of exerts discussed key takeaways happening in the field of cutaneous squamous cell carcinoma. ]]>Fri, 19 Jun 2026 14:00:00 GMTCancerNetworkusCancerNetwork Articleshttps://www.cancernetwork.com/view/59-racialized-economic-segregation-and-insurance-disadvantage-as-mediators-of-racial-disparities-in-breast-cancer-stage-at-diagnosishttps://www.cancernetwork.com/view/59-racialized-economic-segregation-and-insurance-disadvantage-as-mediators-of-racial-disparities-in-breast-cancer-stage-at-diagnosis<![CDATA[In this Florida Cancer Data System mediation analysis, racialized economic segregation and insurance disadvantage explained 29% of the racial disparity in advanced breast cancer stage at diagnosis between Black and White women.]]>Thu, 18 Jun 2026 22:30:00 GMTCancerNetworkusCancerNetwork Articleshttps://www.cancernetwork.com/view/60-racialized-economic-segregation-as-a-mediator-of-racial-disparities-in-triple-negative-breast-cancerhttps://www.cancernetwork.com/view/60-racialized-economic-segregation-as-a-mediator-of-racial-disparities-in-triple-negative-breast-cancer<![CDATA[In this Florida Cancer Data System analysis, structural racism and health insurance disadvantage together mediated nearly 8% of the racial disparity in TNBC between Black and White women.]]>Thu, 18 Jun 2026 22:00:00 GMTCancerNetworkusCancerNetwork Articleshttps://www.cancernetwork.com/view/evaluating-bladder-sparing-strategies-and-key-gu-data-from-asco-2026https://www.cancernetwork.com/view/evaluating-bladder-sparing-strategies-and-key-gu-data-from-asco-2026<![CDATA[New ASCO 2026 data reinforced the importance of multidisciplinary coordination and patient-centered decision-making when considering cystectomy omission.]]>Thu, 18 Jun 2026 20:00:00 GMTCancerNetworkusCancerNetwork Articleshttps://www.cancernetwork.com/view/emerging-t-cell-engagers-and-novel-immunotargets-in-multiple-myelomahttps://www.cancernetwork.com/view/emerging-t-cell-engagers-and-novel-immunotargets-in-multiple-myeloma<![CDATA[The 2025 ICE-T Symposium highlighted expansion beyond BCMA to additional targets such as GPRC5D and FcRH5.]]>Thu, 18 Jun 2026 18:00:00 GMTCancerNetworkusCancerNetwork Articleshttps://www.cancernetwork.com/view/first-line-maintenance-ibrutinib-improves-survival-in-tp53-mutated-mclhttps://www.cancernetwork.com/view/first-line-maintenance-ibrutinib-improves-survival-in-tp53-mutated-mcl<![CDATA[The investigators concluded that the impact of autologous stem cell transplantation with ibrutinib cannot be determined vs ibrutinib alone.]]>Thu, 18 Jun 2026 17:00:00 GMTCancerNetworkusCancerNetwork Articleshttps://www.cancernetwork.com/view/nccn-expands-csf-molecular-profiling-recommendation-to-inoperable-high-grade-gliomahttps://www.cancernetwork.com/view/nccn-expands-csf-molecular-profiling-recommendation-to-inoperable-high-grade-glioma<![CDATA[Updated NCCN guidelines for CNS cancers now recommend CSF-based tumor-derived DNA testing for patients with biopsy-infeasible high-grade glioma or glioblastoma.]]>Thu, 18 Jun 2026 16:00:11 GMTCancerNetworkusCancerNetwork Articleshttps://www.cancernetwork.com/view/revolutionizing-oncology-in-the-digital-age-effects-on-health-care-providershttps://www.cancernetwork.com/view/revolutionizing-oncology-in-the-digital-age-effects-on-health-care-providers<![CDATA[Julie M. Vose, MD, MBA, discussed how the digital age is impacting oncology care. ]]>Thu, 18 Jun 2026 14:00:00 GMTCancerNetworkusCancerNetwork Articleshttps://www.cancernetwork.com/view/61-economic-burden-of-neutropenia-among-patients-treated-for-hr-her2-and-triple-negative-metastatic-breast-cancer-in-the-united-states-a-retrospective-claims-analysishttps://www.cancernetwork.com/view/61-economic-burden-of-neutropenia-among-patients-treated-for-hr-her2-and-triple-negative-metastatic-breast-cancer-in-the-united-states-a-retrospective-claims-analysis<![CDATA[This retrospective claims analysis found neutropenia carried substantial economic burden in HR+/HER2– and triple-negative mBC, with the highest neutropenia-related costs seen during sacituzumab govitecan regimens.]]>Wed, 17 Jun 2026 22:30:00 GMTCancerNetworkusCancerNetwork Articleshttps://www.cancernetwork.com/view/62-integrating-dose-modifications-for-effective-management-of-hr-her2-early-breast-cancer-with-abemaciclibhttps://www.cancernetwork.com/view/62-integrating-dose-modifications-for-effective-management-of-hr-her2-early-breast-cancer-with-abemaciclib<![CDATA[This review of monarchE and TRADE data demonstrates that abemaciclib dose modifications manage treatment-related adverse events without compromising efficacy in high-risk HR+, HER2− early breast cancer.]]>Wed, 17 Jun 2026 22:00:00 GMTCancerNetworkusCancerNetwork Articleshttps://www.cancernetwork.com/view/givastomig-earns-fda-fast-track-designation-in-her2-negative-gastric-cancerhttps://www.cancernetwork.com/view/givastomig-earns-fda-fast-track-designation-in-her2-negative-gastric-cancer<![CDATA[A phase 3 trial with givastomig plus nivolumab and chemotherapy in first-line HER2-negative metastatic gastric cancer is planned in Q4 2026.]]>Wed, 17 Jun 2026 17:00:14 GMTCancerNetworkusCancerNetwork Articleshttps://www.cancernetwork.com/view/from-conference-to-practice-top-5-takeaways-from-eha-2026https://www.cancernetwork.com/view/from-conference-to-practice-top-5-takeaways-from-eha-2026<![CDATA[This year’s EHA Congress saw potential advances across multiple myeloma, leukemia, lymphoma, and other hematologic malignancy populations.]]>Wed, 17 Jun 2026 16:00:00 GMTCancerNetworkusCancerNetwork Articleshttps://www.cancernetwork.com/view/managing-toxicities-associated-with-adcs-in-metastatic-tnbchttps://www.cancernetwork.com/view/managing-toxicities-associated-with-adcs-in-metastatic-tnbc<![CDATA[Treatment with ADCs for metastatic TNBC comes with a unique set of toxicities, and know how to manage, or adjust treatment as needed is important. ]]>Wed, 17 Jun 2026 14:00:00 GMTCancerNetworkusCancerNetwork Articleshttps://www.cancernetwork.com/view/historical-evolution-and-current-treatment-landscapehttps://www.cancernetwork.com/view/historical-evolution-and-current-treatment-landscape<![CDATA[Dr. Joshua Zeidner from University of North Carolina Lineberger Comprehensive Cancer Center and Dr. Jorge Cortes from O'Neal Cancer Center at University of Alabama Birmingham introduce their discussion on frontline chronic myeloid leukemia (CML) management. ]]>Wed, 17 Jun 2026 12:00:00 GMTCancerNetworkusCancerNetwork Articleshttps://www.cancernetwork.com/view/63-patient-and-provider-related-diagnostic-delay-in-pregnancy-associated-breast-cancer-a-descriptive-systematic-reviewhttps://www.cancernetwork.com/view/63-patient-and-provider-related-diagnostic-delay-in-pregnancy-associated-breast-cancer-a-descriptive-systematic-review<![CDATA[This descriptive systematic review of 14 studies found diagnostic delay in PABC was common and multifactorial, driven by both patient- and provider-related factors including symptom misattribution to pregnancy.]]>Tue, 16 Jun 2026 22:30:00 GMTCancerNetworkusCancerNetwork Articleshttps://www.cancernetwork.com/view/64-a-phase-i-ii-study-of-pembrolizumab-and-anti-cd3-x-anti-her2-armed-activated-t-cells-in-metastatic-breast-cancerhttps://www.cancernetwork.com/view/64-a-phase-i-ii-study-of-pembrolizumab-and-anti-cd3-x-anti-her2-armed-activated-t-cells-in-metastatic-breast-cancer<![CDATA[This phase 1/2 trial assessed HER2 BATs combined with pembrolizumab in metastatic breast cancer, finding the regimen safe and well tolerated with stable disease as the best response in 17 evaluable patients.]]>Tue, 16 Jun 2026 22:00:00 GMTCancerNetworkusCancerNetwork Articleshttps://www.cancernetwork.com/view/analyzing-adc-options-across-metastatic-tnbchttps://www.cancernetwork.com/view/analyzing-adc-options-across-metastatic-tnbc<![CDATA[Panelists discussed 4 trials, which focused on 3 different ADCs and how each one is being utilized in their clinical practice.]]>Tue, 16 Jun 2026 20:00:00 GMTCancerNetworkusCancerNetwork Articleshttps://www.cancernetwork.com/view/pembrolizumab-combo-shows-efficacy-in-pediatric-high-risk-hodgkin-lymphomahttps://www.cancernetwork.com/view/pembrolizumab-combo-shows-efficacy-in-pediatric-high-risk-hodgkin-lymphoma<![CDATA[Among 3-to-25-year-old patients with slow, early responses to chemotherapy with newly diagnosed classic Hodgkin lymphoma, pembrolizumab showed an ORR of 98%.]]>Tue, 16 Jun 2026 17:00:00 GMTCancerNetworkusCancerNetwork Articleshttps://www.cancernetwork.com/view/eli-002-7p-misses-primary-end-point-phase-2-amplify-7p-pdac-studyhttps://www.cancernetwork.com/view/eli-002-7p-misses-primary-end-point-phase-2-amplify-7p-pdac-study<![CDATA[The phase 2 AMPLIFY-7P trial did not meet its primary DFS end point, though post-hoc analyses identified a benefit in R0-resected patients with mKRAS PDAC.]]>Tue, 16 Jun 2026 16:30:00 GMTCancerNetworkusCancerNetwork Articleshttps://www.cancernetwork.com/view/cd47-antibody-combo-shows-meaningful-activity-in-previously-untreated-amlhttps://www.cancernetwork.com/view/cd47-antibody-combo-shows-meaningful-activity-in-previously-untreated-aml<![CDATA[Data from a phase 2 trial support further clinical development of AK117 in previously untreated acute myeloid leukemia.]]>Tue, 16 Jun 2026 16:00:00 GMTCancerNetworkusCancerNetwork Articleshttps://www.cancernetwork.com/view/fda-accepts-bla-for-ozekibart-in-unresectable-or-metastatic-chondrosarcomahttps://www.cancernetwork.com/view/fda-accepts-bla-for-ozekibart-in-unresectable-or-metastatic-chondrosarcoma<![CDATA[The FDA has accepted the BLA for ozekibart in unresectable or metastatic conventional chondrosarcoma, setting a PDUFA goal date of April 14, 2027.]]>Tue, 16 Jun 2026 15:00:00 GMTCancerNetworkusCancerNetwork Articleshttps://www.cancernetwork.com/view/elucidating-first-line-sc-mosunetuzumab-benefit-in-follicular-lymphomahttps://www.cancernetwork.com/view/elucidating-first-line-sc-mosunetuzumab-benefit-in-follicular-lymphoma<![CDATA[Emmanuel Bachy, MD, PhD, shared data from a phase 1b study evaluating subcutaneous mosunetuzumab plus lenalidomide in untreated follicular lymphoma.]]>Tue, 16 Jun 2026 12:00:00 GMTCancerNetworkusCancerNetwork Articleshttps://www.cancernetwork.com/view/tip65-the-impact-of-aromatase-inhibitor-use-on-cardiorespiratory-fitness-in-post-menopausal-breast-cancer-patientshttps://www.cancernetwork.com/view/tip65-the-impact-of-aromatase-inhibitor-use-on-cardiorespiratory-fitness-in-post-menopausal-breast-cancer-patients<![CDATA[This prospective, single-arm observational trial examines whether aromatase inhibitor therapy in postmenopausal women with HR-positive breast cancer adversely affects cardiorespiratory fitness, skeletal muscle function, and immunosenescence.]]>Mon, 15 Jun 2026 22:30:00 GMTCancerNetworkusCancerNetwork Articleshttps://www.cancernetwork.com/view/tip66-feasibility-of-the-thrive-wellness-program-for-young-breast-cancer-survivors-a-multicenter-pilot-trialhttps://www.cancernetwork.com/view/tip66-feasibility-of-the-thrive-wellness-program-for-young-breast-cancer-survivors-a-multicenter-pilot-trial<![CDATA[This randomized multicenter pilot trial assesses feasibility of the THRIVE Wellness Program, a 6-week lifestyle intervention for young breast cancer survivors aged 40 years or younger.]]>Mon, 15 Jun 2026 22:00:00 GMTCancerNetworkusCancerNetwork Articleshttps://www.cancernetwork.com/view/belantamab-mafodotin-regimen-yields-enduring-responses-in-ndmmhttps://www.cancernetwork.com/view/belantamab-mafodotin-regimen-yields-enduring-responses-in-ndmm<![CDATA[Data from a phase 1/2 trial show durable disease control with belantamab mafodotin plus daratumumab, lenalidomide, and dexamethasone.]]>Mon, 15 Jun 2026 20:29:14 GMTCancerNetworkusCancerNetwork Articleshttps://www.cancernetwork.com/view/fda-approves-gadoquatrane-detect-cns-body-region-lesionshttps://www.cancernetwork.com/view/fda-approves-gadoquatrane-detect-cns-body-region-lesions<![CDATA[The FDA has approved gadoquatrane for contrast-enhanced MRI to detect lesions with abnormal vascularity in the central nervous system and body.]]>Mon, 15 Jun 2026 20:00:05 GMTCancerNetworkusCancerNetwork Articleshttps://www.cancernetwork.com/view/brentuximab-vedotin-chemo-regimens-show-similar-efficacy-in-2l-lymphomahttps://www.cancernetwork.com/view/brentuximab-vedotin-chemo-regimens-show-similar-efficacy-in-2l-lymphoma<![CDATA[Brentuximab vedotin plus ifosfamide, carboplatin, and etoposide conferred significantly increased toxicity vs 2 other chemotherapy-containing regimens.]]>Mon, 15 Jun 2026 19:00:00 GMTCancerNetworkusCancerNetwork Articles